Protagonist Therapeutics Inc
NASDAQ:PTGX

Watchlist Manager
Protagonist Therapeutics Inc Logo
Protagonist Therapeutics Inc
NASDAQ:PTGX
Watchlist
Price: 42.67 USD -1.16% Market Closed
Market Cap: 2.5B USD
Have any thoughts about
Protagonist Therapeutics Inc?
Write Note

P/E
Price to Earnings

14.9
Current
-6.1
Median
23
Industry
Higher than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
14.9
=
Market Cap
2.5B USD
/
Net Income
170.8m USD
All Countries
Close
Earnings Growth
US
Protagonist Therapeutics Inc
NASDAQ:PTGX
Average P/E: 180.2
14.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.2
412%
US
Amgen Inc
NASDAQ:AMGN
38.3
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.7
42%
US
Gilead Sciences Inc
NASDAQ:GILD
916
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
21.4
2-Years Forward
P/E
-29.6
3-Years Forward
P/E
-21.5

See Also

Discover More